<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Giehrl-Schwab J</submitter><funding>Helmholtz Association</funding><funding>Else Kröner-Fresenius-Stiftung</funding><funding>Chan Zuckerberg Initiative</funding><pagination>e14797</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9081909</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(5)</volume><pubmed_abstract>Direct reprogramming based on genetic factors resembles a promising strategy to replace lost cells in degenerative diseases such as Parkinson's disease. For this, we developed a knock-in mouse line carrying a dual dCas9 transactivator system (dCAM) allowing the conditional in vivo activation of endogenous genes. To enable a translational application, we additionally established an AAV-based strategy carrying intein-split-dCas9 in combination with activators (AAV-dCAS). Both approaches were successful in reprogramming striatal astrocytes into induced GABAergic neurons confirmed by single-cell transcriptome analysis of reprogrammed neurons in vivo. These GABAergic neurons functionally integrate into striatal circuits, alleviating voluntary motor behavior aspects in a 6-OHDA Parkinson's disea</pubmed_abstract><journal>EMBO molecular medicine</journal><pubmed_title>Parkinson's disease motor symptoms rescue by CRISPRa-reprogramming astrocytes into GABAergic neurons.</pubmed_title><pmcid>PMC9081909</pmcid><funding_grant_id>ZT‐I‐0007</funding_grant_id><funding_grant_id>2018/T20</funding_grant_id><funding_grant_id>xNet‐0041‐Phase2‐3</funding_grant_id><pubmed_authors>Gotz M</pubmed_authors><pubmed_authors>Ibarra IL</pubmed_authors><pubmed_authors>Luecken MD</pubmed_authors><pubmed_authors>Holter SM</pubmed_authors><pubmed_authors>Koupourtidou C</pubmed_authors><pubmed_authors>Theis FJ</pubmed_authors><pubmed_authors>Ninkovic J</pubmed_authors><pubmed_authors>Wurst W</pubmed_authors><pubmed_authors>Masserdotti G</pubmed_authors><pubmed_authors>Truong DJ</pubmed_authors><pubmed_authors>Giesert F</pubmed_authors><pubmed_authors>Prakash N</pubmed_authors><pubmed_authors>Lao CL</pubmed_authors><pubmed_authors>Vogt Weisenhorn DM</pubmed_authors><pubmed_authors>Lefort S</pubmed_authors><pubmed_authors>Hembach S</pubmed_authors><pubmed_authors>Rauser B</pubmed_authors><pubmed_authors>Fischer-Sternjak J</pubmed_authors><pubmed_authors>Giehrl-Schwab J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Parkinson's disease motor symptoms rescue by CRISPRa-reprogramming astrocytes into GABAergic neurons.</name><description>Direct reprogramming based on genetic factors resembles a promising strategy to replace lost cells in degenerative diseases such as Parkinson's disease. For this, we developed a knock-in mouse line carrying a dual dCas9 transactivator system (dCAM) allowing the conditional in vivo activation of endogenous genes. To enable a translational application, we additionally established an AAV-based strategy carrying intein-split-dCas9 in combination with activators (AAV-dCAS). Both approaches were successful in reprogramming striatal astrocytes into induced GABAergic neurons confirmed by single-cell transcriptome analysis of reprogrammed neurons in vivo. These GABAergic neurons functionally integrate into striatal circuits, alleviating voluntary motor behavior aspects in a 6-OHDA Parkinson's disea</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2025-04-04T20:35:41.655Z</modification><creation>2025-02-19T03:58:46.186Z</creation></dates><accession>S-EPMC9081909</accession><cross_references><pubmed>35373464</pubmed><doi>10.15252/emmm.202114797</doi></cross_references></HashMap>